Compare Cadila Healthcare with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs LUPIN - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE LUPIN CADILA HEALTHCARE/
LUPIN
 
P/E (TTM) x 35.4 47.0 75.3% View Chart
P/BV x 6.2 4.3 143.7% View Chart
Dividend Yield % 0.6 0.5 110.9%  

Financials

 CADILA HEALTHCARE   LUPIN
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
LUPIN
Mar-20
CADILA HEALTHCARE/
LUPIN
5-Yr Chart
Click to enlarge
High Rs352882 39.9%   
Low Rs207505 40.9%   
Sales per share (Unadj.) Rs139.2339.4 41.0%  
Earnings per share (Unadj.) Rs11.8-5.9 -197.8%  
Cash flow per share (Unadj.) Rs18.615.5 120.0%  
Dividends per share (Unadj.) Rs3.506.00 58.3%  
Dividend yield (eoy) %1.30.9 144.8%  
Book value per share (Unadj.) Rs101.4276.7 36.6%  
Shares outstanding (eoy) m1,023.74453.00 226.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.02.0 98.2%   
Avg P/E ratio x23.7-116.6 -20.4%  
P/CF ratio (eoy) x15.044.8 33.6%  
Price / Book Value ratio x2.82.5 110.0%  
Dividend payout %29.8-100.9 -29.5%   
Avg Mkt Cap Rs m286,033314,201 91.0%   
No. of employees `00013.418.3 73.2%   
Total wages/salary Rs m24,14529,868 80.8%   
Avg. sales/employee Rs Th10,632.78,400.6 126.6%   
Avg. wages/employee Rs Th1,801.21,632.0 110.4%   
Avg. net profit/employee Rs Th898.5-147.2 -610.4%   
INCOME DATA
Net Sales Rs m142,531153,748 92.7%  
Other income Rs m1,1394,838 23.5%   
Total revenues Rs m143,670158,585 90.6%   
Gross profit Rs m24,19824,849 97.4%  
Depreciation Rs m6,9659,702 71.8%   
Interest Rs m3,4183,630 94.2%   
Profit before tax Rs m14,95416,355 91.4%   
Minority Interest Rs m2884 7,384.6%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m3,19811,571 27.6%   
Profit after tax Rs m12,044-2,694 -447.1%  
Gross profit margin %17.016.2 105.0%  
Effective tax rate %21.470.8 30.2%   
Net profit margin %8.5-1.8 -482.3%  
BALANCE SHEET DATA
Current assets Rs m87,154154,132 56.5%   
Current liabilities Rs m82,69492,252 89.6%   
Net working cap to sales %3.140.2 7.8%  
Current ratio x1.11.7 63.1%  
Inventory Days Days7182 87.0%  
Debtors Days Days94129 72.6%  
Net fixed assets Rs m133,23689,082 149.6%   
Share capital Rs m1,024906 113.0%   
"Free" reserves Rs m102,733124,461 82.5%   
Net worth Rs m103,757125,367 82.8%   
Long term debt Rs m32,14617,933 179.3%   
Total assets Rs m236,866249,839 94.8%  
Interest coverage x5.45.5 97.6%   
Debt to equity ratio x0.30.1 216.6%  
Sales to assets ratio x0.60.6 97.8%   
Return on assets %6.50.4 1,742.6%  
Return on equity %11.6-2.1 -540.2%  
Return on capital %13.78.7 157.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75251,450 102.5%   
Fx outflow Rs m14,50419,470 74.5%   
Net fx Rs m38,24831,980 119.6%   
CASH FLOW
From Operations Rs m25,05414,688 170.6%  
From Investments Rs m-10,12311,070 -91.4%  
From Financial Activity Rs m-10,942-8,906 122.9%  
Net Cashflow Rs m3,98916,853 23.7%  

Share Holding

Indian Promoters % 74.8 46.6 160.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.3 11.3 73.5%  
FIIs % 5.9 31.9 18.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.1 108.9%  
Shareholders   44,069 98,259 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   UNICHEM LAB  AUROBINDO PHARMA  STERLING BIOTECH  GLENMARK PHARMA  SUN PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Trades Flat, Interglobe Aviation QIP, Rising Premium for Non-Life Insurers, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended lower yesterday. Benchmark indices ended nearly 1% lower, tracking weakness in global markets and dragged primarily by finance and banking stocks.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 11, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - TORRENT PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS